{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:01:09Z","timestamp":1791806469401,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jconrel.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:36:11Z","timestamp":1717220171000},"page":"288-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model"],"prefix":"10.1016","volume":"371","author":[{"given":"Christian Ammitzb\u00f8ll","family":"Juul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Bj\u00f8rnbo","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikke Petrine","family":"Fliedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ringgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Eliasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Rosager","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Ringkj\u00f8bing","family":"Elema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Elias","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Lars","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.05.005_bb0005","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(74)90682-5","article-title":"Drug-carrier potential of liposomes in cancer chemotherapy","volume":"1","author":"Gregoriadis","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1039\/D2BM01252A","article-title":"Pharmaceutical liposomal delivery-specific considerations of innovation and challenges","volume":"11","author":"Peng","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1018907715905","article-title":"Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs","volume":"10","author":"Gabizon","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0020","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0025","first-page":"3352","article-title":"Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0030","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bjc.6603581","article-title":"In ovarian cancer the prognostic influence of HER2\/neu is not dependent on the CXCR4\/SDF-1 signalling pathway","volume":"96","author":"Pils","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","article-title":"HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician\u2019s choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced\/metastatic breast cancer","volume":"16","author":"Miller","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.10329","article-title":"Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets","volume":"99","author":"Vihinen","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biochi.2005.01.014","article-title":"Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers","volume":"87","author":"Turpeenniemi-Hujanen","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0070","doi-asserted-by":"crossref","first-page":"17867","DOI":"10.1073\/pnas.0408191101","article-title":"Tumor imaging by means of proteolytic activation of cell-penetrating peptides","volume":"101","author":"Jiang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.gt.3302843","article-title":"Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid","volume":"14","author":"Hatakeyama","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba5628","article-title":"Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy","volume":"6","author":"Ringgaard","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0085","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1021\/acsami.5b04612","article-title":"Remote loading of (64)cu(2+) into liposomes without the use of ion transport enhancers","volume":"7","author":"Henriksen","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0090","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4161\/cbt.21782","article-title":"Reporting of preclinical tumor-graft cancer therapeutic studies","volume":"13","author":"Sugar","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114079","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0100","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1007\/s00216-020-02592-x","article-title":"Monitoring cell endocytosis of liposomes by real-time electrical impedance spectroscopy","volume":"412","author":"Caviglia","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2015.06.026","article-title":"Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach","volume":"94","author":"Soema","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1073\/pnas.92.5.1327","article-title":"Development of anti-p185HER2 immunoliposomes for cancer therapy","volume":"92","author":"Park","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0120","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2009.02.002","article-title":"Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage","volume":"136","author":"Shmeeda","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1432-1033.1990.tb19462.x","article-title":"Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties","volume":"194","author":"Okada","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-003-0719-4","article-title":"Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma","volume":"53","author":"Zamboni","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0140","first-page":"541","article-title":"Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer","volume":"30","author":"Seetharamu","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0145","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1073\/pnas.0910283107","article-title":"Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases","volume":"107","author":"Olson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0150","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/nn300524f","article-title":"Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting","volume":"6","author":"Zhu","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0155","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s11095-007-9425-y","article-title":"Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells","volume":"24","author":"Yang","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0160","doi-asserted-by":"crossref","first-page":"11386","DOI":"10.1021\/acsnano.8b06266","article-title":"Theranostic imaging may vaccinate against the therapeutic benefit of long circulating PEGylated liposomes and change cargo pharmacokinetics","volume":"12","author":"Borresen","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2017.06.024","article-title":"Revisiting the use of sPLA(2)-sensitive liposomes in cancer therapy","volume":"261","author":"Pourhassan","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2017.07.031","article-title":"Secretory phospholipase a(2) responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo","volume":"262","author":"Ostrem","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0180","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.4049\/jimmunol.1402891","article-title":"Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages","volume":"194","author":"Shi","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.05.005_bb0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.005_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.05.042","article-title":"The hard protein corona of stealth liposomes is sparse","volume":"307","author":"Kristensen","year":"2019","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400289X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400289X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:07:40Z","timestamp":1719281260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592400289X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"alternative-id":["S016836592400289X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.005","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}